Literature DB >> 10226071

Anti-inflammatory actions of interleukin-13: suppression of tumor necrosis factor-alpha and antigen-induced leukocyte accumulation in the guinea pig lung.

M L Watson1, A M White, E M Campbell, A W Smith, J Uddin, T Yoshimura, J Westwick.   

Abstract

The Th2 cytokine interleukin (IL)-13 is believed to play an important role in the development of allergy, although it has also been ascribed anti-inflammatory roles in several experimental models. In this study, we have examined the effects of human recombinant IL-13 on eosinophilic lung inflammation in the guinea pig. IL-13 (1 to 100 ng, given by intratracheal instillation) did not elicit airway eosinophil recruitment. A pronounced accumulation of eosinophils, as well as monocyte/macrophages, was elicited by intratracheal instillation of guinea pig tumor necrosis factor alpha (gpTNF-alpha). Intratracheal administration of IL-13 (1 to 100 ng) given immediately prior to exposure to gpTNF-alpha resulted in a dose-related suppression of eosinophil and monocyte/macrophage accumulation in the airways, as assessed by bronchoalveolar lavage (BAL) and eosinophil peroxidase activity in whole-lung homogenates. IL-13 treatment also reduced BAL fluid (BALF) leukocyte accumulation induced by subsequent aerosol antigen challenge of sensitized guinea pigs. Antigen challenge also resulted in elevated levels of immunoreactive eotaxin and eosinophil-stimulating activity in BALF, although only the latter was reduced significantly by IL-13 instillation prior to challenge. In contrast to the suppressive effects of IL-13, instillation of human recombinant IL-4 (100 ng) alone elicited an increase in BALF monocyte/macrophage numbers, and IL-4 was unable to inhibit gpTNF-alpha-induced leukocyte accumulation. Hence, IL-13 (but not human IL-4) exhibits an anti-inflammatory action in the airways of gpTNF-alpha- or antigen-challenged guinea pigs, by mechanisms that may involve the decreased generation of eosinophil-stimulating activity in the airways.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10226071     DOI: 10.1165/ajrcmb.20.5.3540

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  7 in total

1.  IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury.

Authors:  J Corne; G Chupp; C G Lee; R J Homer; Z Zhu; Q Chen; B Ma; Y Du; F Roux; J McArdle; A B Waxman; J A Elias
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

2.  Effect of transgenic overexpression of FLIP on lymphocytes on development and resolution of experimental autoimmune thyroiditis.

Authors:  Yujiang Fang; Gordon C Sharp; Helen Braley-Mullen
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

3.  Effect of pulsed electromagnetic field (PEMF) on infarct size and inflammation after cerebral ischemia in mice.

Authors:  Juan Carlos Pena-Philippides; Yirong Yang; Olga Bragina; Sean Hagberg; Edwin Nemoto; Tamara Roitbak
Journal:  Transl Stroke Res       Date:  2014-02-20       Impact factor: 6.829

4.  Increased interleukin-13 expression in patients with sarcoidosis.

Authors:  H-P Hauber; D Gholami; A Meyer; A Pforte
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

5.  NK cells modulate the cytotoxic activity generated by Mycobacterium leprae-hsp65 in leprosy patients: role of IL-18 and IL-13.

Authors:  S de la Barrera; M Finiasz; S Fink; J Ilarregui; M Aleman; L Olivares; M C Franco; G Pizzariello; M del Carmen Sasiain
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

Review 6.  Alveolar Macrophage Polarisation in Lung Cancer.

Authors:  Saleh A Almatroodi; Christine F McDonald; Dodie S Pouniotis
Journal:  Lung Cancer Int       Date:  2014-05-08

7.  Characterization of pentraxin 3 in the horse and its expression in airways.

Authors:  Eve Ramery; Laurence Fievez; Audrey Fraipont; Fabrice Bureau; Pierre Lekeux
Journal:  Vet Res       Date:  2009-10-29       Impact factor: 3.683

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.